Marijuana

Adolescent Medicine: State of the Art Reviews

Volumn 25, Issue 1, 2014, Pages 70-88

  Ammerman, Seth ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; MEDICAL CANNABIS;

ADOLESCENT; ADOLESCENT BEHAVIOR; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CAR DRIVING; FAMILY RELATION; HUMAN; MEDICINE; SOCIAL JUSTICE; TOBACCO DEPENDENCE; UNITED STATES;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT MEDICINE; ALCOHOLISM; AUTOMOBILE DRIVING; CANNABINOIDS; FAMILY RELATIONS; HUMANS; MARIJUANA ABUSE; MEDICAL MARIJUANA; SOCIAL JUSTICE; TOBACCO USE DISORDER; UNITED STATES;

EID: 84903160096     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Holland I, ed. The Pot Book A Complete Guide to Cannabis: Its Role in Medicine, Politics, Science, and Culture. Rochester, VT: Park Street Press; 2010.
2. Aggarwal SK, Carter GT, Sullivan MD, et al. Medicinal use of cannabis in the United States: his-torical perspectives, current trends, and future directions. J Opoid Manag. 2009;5(3):153-168.
3. Cotter J. Efficacy of crude marijuana and synthetic delta-9- tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: A systematic literature review. Oncol Nursing Forum. 2009;36(3):345-352.
4. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160(3):480-498.
5. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713-737.
6. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: A systemic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-744.
7. Peat S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010;16(10):481-485.
8. Nevalainen T. Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid recep-tor ligands. CurrMed Chem. 2014;21(2):187-203.
9. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Land B BiolSci. 2012:367(1607): 3353-363.
10. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;6:CD009270.
11. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344-552.
12. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569-577.
13. Penner E, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insu-lin resistance among US adults. Am J Med. 2013;126(7):583-589.
14. Navari RM. Antiemetic control: Toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009;10(4):629-644.
15. Pooyania S, Ethans K, Szturm T, et al A randomized, double-blinded, crossover pilot study assess-ing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil. 2010;91 (5):703-77.
16. Sastre-Garriga J, Vila C, Clissql S, et al. THC and CBD oromucosal spray (Sativex) in the manage-ment of spasticity associated with multiple sclerosis. Expert Rev Neurother. 2011;11(5):627-637.
17. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: A systematic review. CMAJ. 2008;178:1669-1678.
18. Monitoring The Future. 2010 Data Tables, Table 3. National Institute on Drug Abuse 8c The Insti-tute for Social Research, University of Michigan. Available at: www.monitoringthefuture.org/data/10data/pr10t3.pdf Accessed November 30, 2013.
19. Centers for Disease Control and Prevention. Youth risk behavior surveillance system. 2012. Avail-able at: www.cdc.gov/HealthyYouth/yrbs. Accessed November 30, 2013.
20. National Survey on Drug Use and Health. Substance abuse and mental health services administration, Research Triangle Institute. Available at: nsduhweb.rti.org. Accessed November 30, 2013.
21. The Partnership Attitude Tracking Study, MetLife Foundation & The Partnership at Drugfree.org, 2011. Parents and teens full report, released May 2, 2012. Available at: www.metlife.com/assets/cao/foundation/PATSFULL- ReportFINAL-May.pdf. Accessed November 30, 2013.
22. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Results of the 2010 national survey of drug use and health: Summary of national findings. Available at oas.samhsa.gov/NSDUH/2kl 0NSDUH/2kl0Results.htm# 1.1. Accessed November 30, 2013.
23. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013:33(2): 195-209.
24. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: A systematic review. CMAJ. 2008;178:1669-78.
25. Appelboam A, Oades PJ. Coma due to Cannabis toxicity in an infant. Eur J Emerg Med. 2006; 13(3): 177-179.
26. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 2013;167(7):630-633.
27. Yakovlev PI, Lecours AR. The myelogenetic cycles of regional maturation of the brain. In: Minkowski A, ed. Regional Development of the Brain in Early Life. Boston, MA: Blackwell Scientific; 1967:3-70.
28. Sowell ER, Thompson PM, Welcome SE, Kan E, Toga AW. Longitudinal mapping of cortical thick-ness and brain growth in normal children. J Neurosci. 2004;24(38):8223-8231.
29. Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci. 2004;1021:77-85.
30. Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post- Adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999;2(10):859-861.
31. Huppi PS, Dubois J. Diffusion tensor imaging of brain development. Semin Petal Neonatal Med. 2006;11:489-497.
32. Gogtay N, Giedd JN, Lusk L, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA. 2004;101:8174-8179.
33. Luna B, Sweeney JA. The emergence of collaborative brain function: fMRI studies of the development of response inhibition. Ann N YAcad Sci. 2004;1021:296-309.
34. Schepis TS, Adinoff B, Rao U. Neurobiological processes in adolescent addictive disorders. Am J Addict. 2008;17(1):6-23.
35. Casey BJ, Getz S, Galvan A. The adolescent brain. Dev Rev. 2008;28(1):62-77.
36. Winters KC, Lee C-Y. Likelihood of developing an alcohol and cannabis use disorder during youth: Association with recent use and age. Drug Alcohol Depend. 2008; 92:239-247.
37. Casey BJ, Jones RM. Neurobiology of the adolescent brain and behavior: implications for sub-stance use disorders. J Am Acad Child Adolesc Psychiatry. 2010;49(12):1189-201; quiz 1285.
38. Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse, and dependence during the first decades of life. Addiction. 2008;103(3):439-449.
39. Von Sydow K, Lieb R, Pfister H, et al. The natural course of cannabis use, abuse, and dependence over four years: A longitudinal community study of adolescents and young adults. Drug Alcohol Depend. 2001;64(3):347-361.
40. Medina KL, Hanson K, Schweinsburg AD, et al. Neuopsychological functioning in adolescent marijuana users: subtle deficits detectable after 30 days of abstinence. J Int Neuropsychol Soc. 2007;13(5):207-220.
41. Gonzalez R, Swanson JM. Long-term effects of adolescent-onset and persistent use of cannabis. Proc Natl Acad Sci USA. 2012; 109(40): 15970-15971.
42. Meier MH, Caspi A, Ambler A, et al Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109(40):E2657-E2664.
43. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consis- Tent with confounding from socioeconomic status. Proc Natl Acad Sci USA. 2013, 110(11):42514242.
44. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and com-bined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol Teratol. 2007;29:141-152.
45. Nagel BJ, Schweinsburg AD, Phan V, Tapert SF. Reduced hippocampal volume among adolescents with alcohol use disorders without psychiatric comorbidity. Psychiatry Res. 2005;139:181-190.
46. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Schweinsburg AD, Tapert SF. Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects. Alcohol Clin Exp Res. 2008;32(3):386-394.
47. Schweinsburg AD, Nagel BJ, Schweinsburg BC, et al. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res. 2008;163:40-51.
48. Squeglia LM, Jacobus J, Tapert SF. The influence of substance use on adolescent brain development. Clin EEG Neurosci. 2009;40(1):31-38.
49. ProCon.org. 20 Legal Medical Marijuana States and D.C. Laws, Fees, and Possession Limits. Summary. Available at: medicalmarijuana.procon.org/view. resource.php?resourceID=000881. Accessed November 30, 2013.
50. Hazekamp A, Ruhaak R, van Gerven J, et al. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006;95:1308-1317.
51. Abrams VI, Vizoszo HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther. 2007;82(5):572-578.
52. Fischedick J, Van Der Kooy F, Verpoorte R. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L smoke and vapor. Chem Pharm Bull. 2010;58(2):201-207.
53. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
54. Wall MM, Poh E, Cerdi M, Keyes KM, Galea S, Hasin DS. Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. Ann Epidemiol. 2011;21(9): 714-716.
55. Marijuana Policy Project. Marijuana: decriminalization vs. tax 8c regulate. Available at: www.mpp.org/legislation/approaches.html. Accessed November 30, 2013.
56. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Results of the 2011 national survey of drug use and health: Summary of national nindings. Available at: www.samhsa.gov/data/nsduh/2kllresults/ nsduhresults2011.htm. Accessed November 30, 2013.
57. Levy DT, Boyle RG, Abrams DB. The role of public policies in reducing smoking: The Minnesota SimSmoke tobacco policy model. Am J PrevMed. 2012;43(5 Suppl 3):S179-S186.
58. Clapp JD, Johnson M, Voas RB, Lange JE, Shilllngton A, Russell C. Reducing DUI among US col-lege students: results of an environmental prevention trial. Addiction. 2005;100(3):327-334.
59. Perkins HW, Linkenbach JW, Lewis MA, Neighbors C Effectiveness of social norms media marketing in reducing drinking and driving: A statewide campaign. Addict Behav. 2010;35(10):866-874.
60. Drugscience.org. Marijuana, science, and public policy. Marijuana arrests in the United States, (2007). A special report in the November, 2009 edition of the Bulletin of Cannabis reform. Available at: www.drugscience.org. Accessed November 30, 2013.
61. US Census Bureau. Annual county resident population estimates by age, sex, race, and Hispanic origin. 2010. Available at: 2010.census.gov/2010census/ data/index.php. Accessed November 30, 2013.
62. National Organization for the Reform of Marijuana Laws. States That Have Decriminalized Marijuana Laws. Available at: normLorg/aboutmarijuana/item/ states-that-have-decriminalized. Accessed November 30, 2013.
63. Get Smart About Drugs: A Drug Enforcement Agency Resource for Parents. What are the penalties for possession of marijuana. Available at mobile.getsmartaboutdrugs.com/identify/what- Are-the-penalties-for-possession- or-marijuana.html Accessed November 30, 2013.
64. The National Survey on Drug Use and Health. The NSDUH Report Published February 27, 2004. Available atwww.samhsa.gov/data/2k4/DetainedYouth/ detainedYouth.pdf. Accessed November 30, 2013.
65. US Department of Justice, Office of Justice Programs, Bureau of Justice Assistance. Juvenile drug courts: strategies in practice monograph. March 2003. Available at: www.ncjrs.gov/pdfi51esl/bjaA97866.pdf. Accessed November 30, 2013.
66. The National Survey on Drug Use and Health. The NSDUH Report Published March 12, 2004. Available at www.samhsa.gov/data/2k4/MJsource/MJsource.pdf. Accessed November 30, 2013.
67. US Department of Transportation, National Highway Traffic Safety Administration. State of knowledge of drugged driving: final report. September 2003. Available at: www.nhtsa.gov/people/injury/research/stateofknwlegedrugs/ stateofknwlegedrugs/. Accessed November 30, 2013.
68. Ramaekers JG, Berghaus G. Dose related risk of motor vehicle crashes after cannabis use: An update. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ, eds. Drugs, Driving, and Traffic Safety. Geneva, Switzerland, World Health Organization, 2009:477-499.
69. US Department of lYansportation, National Highway Traffic Safety Administration. Marijuana and actual driving performance: final report. 1993. Available at: ntl.bts.gov/lib/25000/25800/25867/DOT-HS-808-078.pdf. November 1993. Accessed November 30, 2013.
70. Elliott M, Smith A, La Cava C.Marijuana DUI Workgroup: recommendation to the Drug Policy Task Force and Colorado Commission on Criminal and Juvenile Justice. September 1, 2011. Available at: norml.org/pdLfiles/MMIG-Workgroup- Recommendation-9-6-ll.pdf. Accessed November 30, 2013.
71. Salomensen-Sautel S, Sakai JT, Thurstone C, et al. Medical marijuana use in adolescents in substance abuse treatment. J Am Acad Child Adolesc Psychiatry. 2012;51 (7):694-702.
72. American College of Physicians. Supporting research into the therapeutic role of marijuana. Philadelphia: American College of Physicians; 2008: Position Paper. (Available from American Col-lege of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106). Available at www.acponline.org/acp-policy/ policies/supporting-medmarijuana-2008.pdf Accessed November 30, 2013.
73. California Society of Addiction Medicine (CSAM). CSAM statement on the medical aspects of marijuana legalization. Adopted by the CSAM Executive Council April 2010 Available at www.csam-asam.org/sites/default/files/pdf/misc/ Legalization.pdf.April2010. Accessed November 30, 2013.
74. Procon.org. Medical marijuana, how many people in the United States use medical marijuana? Available at medicalmarijuana.procon.org/view. answers.php'questionID=001199. Accessed November 30, 2013.
75. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.